Art

J-GLOBAL ID：201602235656133054   Reference number：16A1175925

Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells

パノビノスタットとポナチニブの組み合わせはイマチニブ耐性CML細胞を相乗的に克服する

Author (11)： Matsuda Yasufumi (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Yamauchi Takahiro (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Hosono Naoko (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Uzui Kanako (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Negoro Eiju (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Morinaga Koji (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Nishi Rie (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Yoshida Akira (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan) ,  Kimura Shinya (Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University, Saga, Japan) ,  Maekawa Taira (Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan) ,  Ueda Takanori (Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan)
Material： Cancer Science (Web)  (Cancer Sci (Web))
Volume： 107  Issue： 7  Page： 1029-1038  Publication year： 2016 
JST Material Number： U0505A  ISSN： 1349-7006  Document type： Article
Article type： 原著論文  Country of issue： United States (USA)  Language： ENGLISH (EN)

Thesaurus term： *molecular targeting drug ,...
Semi thesaurus term： imatinib resistance ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A1175925&from=J-GLOBAL&jstjournalNo=U0505A") }}

Author keywords (5)： Chronic myelogenous leukemia ,  combination therapy ,  imatinib-resistant ,  panobinostat ,  ponatinib

JST classification (3)： Experimental treatment for tumors  (GE02040Y) ,  Blood cell tumors(=neoplasms)  (GK04000M) ,  Basic research of other drugs  (GW23010K)

Substance index (2)： Panobinostat ,  Ponatinib

Reference (42)：

• Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 1988; 6: 180-2.
• Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277-80.
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-83.
• Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-9.
• Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-82.

Terms in the title (4)： パノビノスタット ,  ポナチニブ ,  組み合わせ ,  イマチニブ耐性